Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

PREGABALIN

PREGABALIN

Standard Dose
82.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview PREGABALIN is listed in Drugs@FDA under application 215675 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient PREGABALIN Form and strength TABLET, EXTENDED RELEASE;ORAL - 82.5MG Sponsor SCIEGEN PHARMS Submission history Latest submission status date: 2022-09-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview PREGABALIN is listed in Drugs@FDA under application 215675 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient PREGABALIN Form and strength TABLET, EXTENDED RELEASE;ORAL - 82.5MG Sponsor SCIEGEN PHARMS Submission history Latest submission status date: 2022-09-14 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.